drugset
Drugs / CD19-BBz(86)
last change Aug 2019 re-read 3 minutes ago

CD19-BBz(86)

also known as CD19-BBz(86) CAR T cells

Cell therapy

Developed for
B-cell neoplasm
Investigated by
Marino Biotechnology Co., Ltd. · Peking University

Trials 1

today NCT02842138 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02842138 Jun 2016 → Feb 2018 B-cell neoplasm Peking University Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as CD19-BBz(86) “Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1BB and CD3ζ domains.” PMID 31011207 ↗ Apr 2019
Known as CD19-BBz(86) CAR T cells “CD19-BBz(86) CAR T cells persistently proliferated and differentiated into memory cells in vivo.” PMID 31011207 ↗ Apr 2019
Modality Cell therapy “CAR T cell therapy” PMID 31011207 ↗ Apr 2019
Route Intravenous “patients are intravenously infused autologous anti-CD19 CAR T cells” NCT02842138 ↗